CVS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

03
Precio $86.46
Capitalización Bursátil (MRQ) $110.50B
P/E (TTM) 22.8
BPA (TTM) $3.79
Ingresos (TTM) $415.09B
Rendimiento div. 3.1%
ROE (TTM) 6.2%
Deuda/Capital 0.0
Rango 52S $70–$111

CVS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

04
rango
barras

La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.

Divisiones de acciones 4
Fecha ex-dividendo División Tipo
7 de junio de 2005 2-for-1 Adelante
16 de junio de 1998 2-for-1 Adelante
15 de marzo de 1989 2-for-1 Adelante
3 de mayo de 1983 2-for-1 Adelante

Acerca de CVS Health Corporation Common Stock Descripción general de la empresa de Wikipedia

05 · wikidata

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

Privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

In September 2026, CVS entered into a $20.5 million class action settlement after a lawsuit alleged that CVS disclosed customers' personal data to advertising company Criteo.

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

sectorHealth Care industriaHealth Care empleados219 000 paísUS

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

06
Ingresos$402.07B
2017-12-31 → 2025-12-31
BPA$1.39
2017-12-31 → 2025-12-31
Flujo de caja libre$7.81B
2017-12-31 → 2025-12-31
Margen neto1.2%
2017-12-31 → 2025-12-31
Valoración y ratios 07–12

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica Tendencia a 5 años CVS promedio 5A Mediana de Pares Veredicto
P/E (TTM) 22.8promedio 5A ≈25.5 ≈25.5 23.3 Sobrevalorado
P/S (TTM) 0.3promedio 5A ≈0.3 ≈0.3 1.3 Infravalorado
P/C (MRQ) 1.4promedio 5A ≈1.4 ≈1.4 2.9 Infravalorado
EV / EBITDA 10.7promedio 5A ≈6.1 ≈6.1 11.4 Infravalorado
Precio / FCF (TTM) 9.4promedio 5A ≈9.9 ≈9.9 · ·
Precio / Flujo de Caja (TTM) 7.5promedio 5A ≈7.6 ≈7.6 9.8 Valor razonable
EV / Revenue (EV / Ingresos) 0.2promedio 5A ≈0.2 ≈0.2 · ·
EV / FCF 12.7promedio 5A ≈9.3 ≈9.3 · ·
Precio / Valor Contable Tangible (MRQ) 2.0 · · ·

La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.

valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana

Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años

13
Rendimiento por Dividendo3.1%
Ratio de Pago192.1%
Pago anualizado≈$2.66Pago trimestral
CAGR de Dividendos a 5 años≈5.9%Por acción, ajustado por splits
Fecha ex-dividendoMontoMonedaRendimiento
Jul 23, 2026$0,67USD≈2.5%
Abr 23, 2026$0,67USD≈3.4%
Ene 22, 2026$0,67USD≈3.2%
Oct 23, 2025$0,67USD≈3.3%
Jul 22, 2025$0,67USD≈4.4%
Abr 22, 2025$0,67USD≈4.1%
Ene 23, 2025$0,67USD≈4.9%
Oct 21, 2024$0,67USD≈4.6%
Jul 22, 2024$0,67USD≈4.5%
Abr 19, 2024$0,67USD≈3.6%
Ene 19, 2024$0,67USD≈3.4%
Oct 19, 2023$0,61USD≈3.4%
Jul 20, 2023$0,61USD≈3.2%
Abr 20, 2023$0,61USD≈3.2%
Ene 19, 2023$0,61USD≈2.6%
Oct 20, 2022$0,55USD≈2.4%
Jul 21, 2022$0,55USD≈2.3%
Abr 21, 2022$0,55USD≈2.0%
Ene 20, 2022$0,55USD≈2.0%
Oct 21, 2021$0,50USD≈2.3%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

14
Sorpresa Media 22.0%
Próximo informe Oct 27, 2026
PeríodoInformeEPS ActualEPS est.Sorpresa
30 de junio de 2026 Jul 29, 2026 $2.58 $1.87 38.0%
31 de marzo de 2026 $2.57 $2.22 15.8%
31 de diciembre de 2025 $1.09 $1.00 8.8%
30 de septiembre de 2025 $1.60 $1.38 15.7%
30 de junio de 2025 $1.81 $1.47 23.0%
31 de marzo de 2025 $2.25 $1.72 30.8%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

15
Estado de resultados 16
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Cost of Revenue $221.17B$206.29B$217.10B$196.89B$175.80B$163.98B$158.72B·$153.45B$146.53B$126.76B
Gross Profit ········$28.55B$28.86B$26.53B
Operating Expenses $397.41B$364.29B$344.03B$314.51B$278.80B$254.79B$244.79B·$18.81B$18.45B$17.05B
Operating Income $4.66B$8.52B$13.74B$7.95B$13.31B$13.91B$11.99B·$9.54B$10.39B$9.47B
Interest Expense ··$2.66B$2.29B$2.50B$2.91B$3.04B·$1.06B$1.08B$859M
Interest Income ········$21M$20M$21M
Other Non-op $112M$99M$88M$169M$182M$206M$124M·$-208M$-28M·
Pretax Income $2.14B$6.15B$11.17B$5.84B$10.54B$9.77B$9.00B·$8.27B$8.64B$8.62B
Income Tax $408M$1.56B$2.81B$1.51B$2.55B$2.57B$2.37B·$1.64B$3.32B$3.39B
Net Income $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
EPS (Basic) $1.40$3.67$6.49$3.29$6.07$5.48$5.10·$6.47$4.93$4.66
EPS (Diluted) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Shares (Basic) 1,267,000,0001,259,000,0001,285,000,0001,312,000,0001,319,000,0001,309,000,0001,301,000,000·1,020,000,0001,073,000,0001,118,000,000
Shares (Diluted) 1,271,000,0001,262,000,0001,290,000,0001,323,000,0001,329,000,0001,314,000,0001,305,000,000·1,024,000,0001,079,000,0001,126,000,000
EBITDA $9.27B$13.11B$18.11B$11.99B$17.70B$18.35B$16.36B·$12.00B$10.34B$9.45B
Balance general 31
Métrica Tendencia 20252024202320222021202020192018201720162015
Cash & Equivalents $8.45B$8.59B$8.20B$12.95B$9.41B$7.85B$5.68B·$1.70B$3.37B$2.46B
Short-term Investments $2.15B$2.41B$3.26B$2.78B$3.12B$3.00B$2.37B·$111M$87M$88M
Receivables $39.78B$36.47B$35.23B$27.28B$24.43B$21.74B$19.62B·$13.18B$12.16B$11.89B
Inventory $19.25B$18.11B$18.02B$19.09B$17.76B$18.50B$17.52B·$15.30B$14.76B$14.00B
Other Current Assets $5.09B$3.08B$3.15B$2.64B$5.29B$5.28B$5.11B$4.53B$945M$660M$722M
Current Assets $74.71B$68.64B$67.86B$65.63B$60.01B$56.37B$50.30B$45.20B$31.23B$31.04B$29.16B
PP&E (Net) ···$12.87B$12.90B$12.61B$12.04B$11.36B$10.29B$10.18B$9.86B
PP&E (Gross) ···$34.60B$33.55B$31.31B$28.93B·$24.29B$22.80B$21.04B
Accum. Depreciation ···$21.48B$20.65B$18.70B$16.89B·$14.00B$12.63B$11.18B
Goodwill $85.48B$91.27B$91.27B$78.15B$79.12B$79.55B$79.75B·$38.45B$38.25B$38.11B
Intangibles $25.51B$27.32B$29.23B$24.80B$29.03B$31.14B$33.12B$36.31B$13.63B$13.51B$13.88B
Other Non-current Assets $7.11B$4.79B$4.66B$4.62B$4.71B$4.62B$4.60B$4.53B$1.42B$1.49B$1.44B
Total Assets $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B$216.67B$95.13B$94.46B$92.44B
Accounts Payable ········$8.86B$7.95B$7.49B
Accrued Liabilities $22.39B$20.81B$23.52B$18.75B$17.67B$14.24B$12.13B$10.66B$6.58B$6.94B$6.83B
Short-term Debt $0$2.12B$200M$0·$0$0·$1.28B$1.87B$0
Current Liabilities $88.69B$84.61B$79.19B$69.42B$67.81B$62.02B$53.30B$45.76B$30.65B$26.25B$23.17B
Capital Leases $13.64B$14.90B$16.03B$16.80B$18.18B$18.76B$18.93B$18.83B$306M··
Deferred Tax $3.83B$3.81B$4.31B$4.02B$6.27B$6.79B$7.29B$7.74B$3.00B$4.21B$4.22B
Other Non-current Liabilities $6.77B$5.43B$6.21B$6.73B$1.90B$2.35B$2.16B$2.26B$1.28B$1.55B$1.54B
Total Liabilities $178.16B$177.49B$173.09B$156.51B$157.62B$161.01B$158.28B$157.95B$57.44B··
Long-term Debt ······$68.48B$72.61B$27.00B$25.70B$27.50B
Total Debt $0$2.12B$200M···$3.78B·$27.00B$27.53B$27.46B
Common Stock ·$18M$18M$18M$17M$17M$17M·$17M$17M$17M
Paid-in Capital ········$32.08B$31.62B$30.95B
Retained Earnings $61.20B$62.84B$61.60B$56.40B$54.91B$49.64B$45.11B$41.09B$43.56B$38.98B$35.51B
Treasury Stock $36.79B$36.82B$33.84B$31.86B$28.17B$28.18B$28.23B·$37.80B$33.45B$28.89B
AOCI $406M$-120M$-297M$-1.26B$965M$1.41B$1.02B·$-165M$-305M$-358M
Stockholders' Equity $75.21B$75.56B$76.46B$71.47B$75.08B$69.39B$63.86B$58.40B$37.69B$36.83B$37.20B
Liabilities + Equity $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B·$95.13B$94.46B$92.44B
Shares Outstanding 1,271,000,0001,260,000,0001,288,000,0001,300,000,0001,322,000,0001,310,000,0001,302,000,000·1,712,000,0001,061,000,0001,101,000,000
Flujo de Efectivo 19
Métrica Tendencia 20252024202320222021202020192018201720162015
D&A $4.61B$4.60B$4.37B$4.22B$4.49B$4.44B$4.37B·$2.48B$2.48B$2.09B
Stock-based Comp $535M$540M$588M$447M$484M$400M$453M·$234M$222M$230M
Deferred Tax $102M$-572M$-676M$-2.03B$-402M$-564M$-649M·$-1.42B$3M$-234M
Amort. of Intangibles $2.00B$2.00B$1.90B$1.80B$2.20B$2.30B$2.40B·$817M$795M$611M
Restructuring ········$215M··
Other Non-cash $3.63B$-72M$804M$9.41B$5.79B$4.41B$2.04B·$93M··
Operating Cash Flow $10.64B$9.11B$13.43B$16.18B$18.27B$15.87B$12.85B·$8.01B$10.14B$8.54B
CapEx $2.83B$2.78B$3.03B$2.73B$2.52B$2.44B$2.46B·$1.92B$2.22B$2.37B
Investing Cash Flow $-5.87B$-7.61B$-20.89B$-5.05B$-5.26B$-5.53B$-3.34B·$-2.88B$-2.47B$-13.42B
Debt Issued $3.97B$7.91B$10.90B$0$987M$9.96B$3.74B·$0$3.46B$14.80B
Net Debt Issued $340M$3.14B$7.73B$-4.21B$-9.27B$-5.67B$-4.60B··$-2.49B$11.90B
Stock Repurchased $0$3.02B$2.01B$3.50B$0$0$0·$4.36B$4.46B$5.00B
Net Stock Activity $0$-3.02B$-2.01B$-3.50B··$0·$-4.36B$-4.46B$-5.00B
Dividends Paid $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B
Financing Cash Flow $-4.94B$-1.14B$2.68B$-10.52B$-11.36B$-7.70B$-7.65B·$-6.75B$-6.76B$4.88B
Net Change in Cash $-172M$359M$-4.78B$614M$1.65B$2.63B$1.85B·$-1.62B$912M$-22M
Taxes Paid $2.17B$1.70B$3.52B$4.12B$3.19B$2.93B$2.72B·$2.91B$3.06B$3.27B
Free Cash Flow $7.81B$6.33B$10.39B$13.45B$15.74B$13.43B$10.39B·$6.09B$7.84B$6.04B
Levered FCF ··$8.40B$11.76B$13.85B$11.29B$8.15B·$5.24B$7.18B$5.52B
Rentabilidad 8
Métrica Tendencia 20252024202320222021202020192018201720162015
Gross Margin ········15.4%16.3%17.3%
Operating Margin 1.2%2.3%3.8%2.4%4.5%5.2%4.7%·5.1%5.8%6.2%
Net Margin 0.44%1.2%2.3%1.3%2.7%2.7%2.6%·3.6%3.0%3.4%
Pretax Margin 0.53%1.7%3.1%1.8%3.6%3.6%3.5%·4.5%4.9%5.6%
EBITDA Margin 2.3%3.5%5.1%3.7%6.1%6.8%6.4%·6.5%5.8%6.2%
ROA 0.70%1.8%3.5%1.8%3.4%3.2%3.0%·7.0%5.7%6.2%
ROE 2.4%6.1%11.3%5.7%10.9%10.8%10.8%·17.8%14.4%13.9%
ROIC 5.0%8.2%13.4%8.1%13.3%14.8%13.1%·11.8%9.9%8.9%
Liquidez y Solvencia 5
Métrica Tendencia 20252024202320222021202020192018201720162015
Current Ratio 0.80.80.90.90.90.90.9·1.01.21.3
Quick Ratio 0.60.60.60.60.50.50.5·0.50.60.6
Debt / Equity 0.00.00.0···0.1·0.70.70.7
LT Debt / Equity ········0.60.70.7
Interest Coverage ··5.23.45.34.83.9·9.09.611.0
Eficiencia 3
Métrica Tendencia 20252024202320222021202020192018201720162015
Asset Turnover 1.61.51.51.41.31.21.2·1.91.91.8
Inventory Turnover 11.811.411.710.79.79.19.3·10.410.39.8
Receivables Turnover 10.510.411.412.512.713.013.8·14.614.814.2
Por Acción 7
Métrica Tendencia 20252024202320222021202020192018201720162015
Book Value / Share $59.18$59.97$59.36$54.63$56.79$52.97$49.05·$37.17$34.71$33.78
Revenue / Share $316.34$295.41$277.35$243.74$219.80$204.49$196.76·$180.43$164.53$136.14
Cash Flow / Share $8.37$7.22$10.41$12.23$13.74$12.07$9.85·$7.82$9.33$7.47
Cash / Share $6.65$6.81$6.36$9.96$7.12$6.00$4.36·$1.67$3.18$2.23
Dividend / Share $2.66$2.66$2.42$2.20$2.00$2.00$2.00·$2.00$1.70$1.40
Dividend Paid / Share ········$2.00··
EPS (TTM) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Tasas de Crecimiento 10
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue YoY 7.8%4.2%10.9%10.4%8.7%······
Revenue CAGR 3Y 7.6%8.5%10.0%········
Revenue CAGR 5Y 8.4%··········
EPS YoY -62.0%-43.4%98.5%-45.9%10.3%······
EPS CAGR 3Y -24.7%-15.3%5.8%········
EPS CAGR 5Y -23.9%··········
Net Income YoY -61.7%-44.7%93.5%-46.1%11.5%······
Net Income CAGR 3Y -25.7%-16.8%5.1%········
Net Income CAGR 5Y -24.4%··········
Dividends Paid CAGR 5Y 5.3%··········
Valoración (TTM) 16
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue TTM $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Net Income TTM $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
Market Cap $100.87B$56.56B$101.70B$121.15B$136.38B$89.47B$96.73B·$73.52B$83.72B$107.64B
Enterprise Value $90.27B$47.69B$90.45B···$92.45B·$98.71B$107.80B$132.56B
P/E 57.112.312.228.617.112.514.6·11.316.121.1
P/S 0.30.20.30.40.50.30.4·0.40.50.7
P/B 1.30.71.31.71.81.31.5·2.02.32.9
P / Cash Flow 9.56.27.67.57.55.67.5·9.28.312.8
P / FCF 12.98.99.89.08.76.79.3·12.110.717.8
EV / EBITDA 9.73.65.0···5.7·8.210.414.0
EV / FCF 11.67.58.7···8.9·16.213.721.9
EV / Revenue 0.20.10.3···0.4·0.50.60.9
Dividend Yield 3.4%6.0%3.1%2.4%1.9%2.9%2.7%·2.8%2.2%1.5%
Earnings Yield 1.8%8.2%8.2%3.5%5.8%8.0%6.8%·8.9%6.2%4.7%
Payout Ratio 192.1%73.1%37.5%70.1%33.2%36.5%39.2%·30.9%34.6%30.1%
Annual Payout $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B

Período más reciente a la izquierda · valores nulos mostrados como ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

16
Métrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $402.07B $372.81B $357.78B $322.47B $292.11B
Margen Operativo % 1.2% 2.3% 3.8% 2.4% 4.5%
Beneficio neto $1.77B $4.61B $8.34B $4.31B $8.00B
EPS Diluido $1.39 $3.66 $6.47 $3.26 $6.02

Propietarios institucionales (13F) 2 275 declarantes · $125.7B total · A fecha de 30 de septiembre de 2026

17

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Tenedores 2 275
Valor en tenencia $125.7B
Nuevas posiciones 314
Posiciones cerradas 93
Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
314 (+117 vs trimestre anterior) 93 (-96 vs trimestre anterior) 799 (+75 vs trimestre anterior) 755 (-20 vs trimestre anterior) +50.0M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
BlackRock, Inc. $12 747 461 705 123 223 409 10,14% Acciones
VANGUARD GROUP INC $9 579 508 282 120 709 530 7,62% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $8 618 974 924 83 315 369 6,86% Acciones
Capital World Investors $7 753 834 783 74 951 955 6,17% Acciones
STATE STREET CORP $6 236 318 558 60 283 408 4,96% Acciones
Dodge & Cox $5 173 820 539 50 012 765 4,12% Acciones
WELLINGTON MANAGEMENT GROUP LLP $3 496 725 140 33 801 113 2,78% Acciones
GEODE CAPITAL MANAGEMENT, LLC $3 079 404 427 29 899 653 2,45% Acciones
FMR LLC $2 991 837 927 28 920 617 2,38% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $2 755 624 444 26 637 259 2,19% Acciones
Capital Research Global Investors $2 516 851 376 24 329 151 2,00% Acciones
BANK OF AMERICA CORP /DE/ $2 398 868 007 23 188 670 1,91% Acciones
JPMORGAN CHASE & CO $2 290 461 677 22 112 970 1,82% Acciones
Invesco Ltd. $2 130 597 379 20 595 431 1,70% Acciones
MORGAN STANLEY $1 924 793 937 18 606 028 1,53% Acciones
NORGES BANK $1 866 126 481 18 038 922 1,49% Acciones
Capital International Investors $1 591 868 430 15 387 600 1,27% Acciones
GOLDMAN SACHS GROUP INC $1 387 451 459 13 411 807 1,10% Acciones
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $1 371 677 011 13 259 314 1,09% Acciones
Davis Selected Advisers $1 227 594 458 11 865 916 0,98% Acciones
PZENA INVESTMENT MANAGEMENT LLC $1 217 558 500 11 769 536 0,97% Acciones
NORTHERN TRUST CORP $1 186 760 815 11 471 830 0,94% Acciones
FRANKLIN RESOURCES INC $1 032 982 350 9 985 330 0,82% Acciones
Legal & General Group Plc $948 946 746 9 172 999 0,76% Acciones
Bank of New York Mellon Corp $932 453 862 9 013 571 0,74% Acciones
Clearbridge Investments, LLC $883 116 767 8 536 952 0,70% Acciones
ROYAL BANK OF CANADA $880 475 000 8 511 113 0,70% Acciones
GQG Partners LLC $822 989 370 7 955 411 0,65% Acciones
AMERIPRISE FINANCIAL INC $821 911 618 7 943 034 0,65% Acciones
Amundi $778 468 900 7 525 080 0,62% Acciones
DIMENSIONAL FUND ADVISORS LP $763 688 490 7 381 983 0,61% Acciones
VANGUARD FIDUCIARY TRUST CO $741 242 940 7 165 229 0,59% Acciones
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $595 969 397 8 298 098 0,47% Acciones
Nuveen, LLC $544 750 652 5 265 836 0,43% Acciones
UBS Group AG $544 267 107 5 261 161 0,43% Acciones
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524 415 257 5 069 263 0,42% Acciones
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $511 339 969 4 942 871 0,41% Acciones
GLENVIEW CAPITAL MANAGEMENT, LLC $499 125 457 4 824 799 0,40% Acciones
CITADEL ADVISORS LLC $497 856 229 4 812 530 0,40% Acciones
DEUTSCHE BANK AG\ $466 633 571 4 510 716 0,37% Acciones
RAYMOND JAMES FINANCIAL INC $449 870 951 4 348 680 0,36% Acciones
SUSQUEHANNA INTERNATIONAL GROUP, LLP $409 796 485 3 961 300 0,33% Opción de compra
Allianz Asset Management GmbH $391 245 314 3 781 975 0,31% Acciones
WELLS FARGO & COMPANY/MN $380 921 357 3 682 178 0,30% Acciones
VIKING GLOBAL INVESTORS LP $378 974 695 3 663 361 0,30% Acciones
Swiss National Bank $371 195 152 3 588 160 0,30% Acciones
National Pension Service $352 166 145 3 404 216 0,28% Acciones
Mitsubishi UFJ Asset Management Co., Ltd. $322 653 390 3 118 927 0,26% Acciones
Russell Investments Group, Ltd. $312 682 898 3 022 292 0,25% Acciones
Holocene Advisors, LP $310 524 210 3 001 684 0,25% Acciones

Mostrar todos los 2 275 propietarios institucionales →

Activistas y propietarios del %+ 5 1 tenencia

18

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
CVS Caremark Corporation 7 de enero de 2011 · Presentación inicial M&A / venta SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Informantes de la empresa 86 insiders · 48 directivos · 41 consejeros

19
Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
David J. Joyner President, CEO and Chair 1 de abril de 2026 F 70 349 0 0 $0
Karen S Lynch President and CEO 1 de abril de 2024 A 74 687 0 0 $0
Brian Newman EVP, Chief Financial Officer 31 de mayo de 2026 F 3 008 0 0 $0
Thomas F. Cowhey EVP and CFO 1 de abril de 2025 A 41 109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer 1 de abril de 2023 A 34 706 0 0 $0
Eva C Boratto EVP & CFO 4 de mayo de 2021 S 115 331 0 0 $0
David M Denton EVP and CFO 29 de noviembre de 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer 14 de diciembre de 2009 M 207 179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv 2 de noviembre de 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer 1 de abril de 2022 A 426 025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer 26 de junio de 2026 F 27 606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer 31 de mayo de 2026 F 9 557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer 8 de mayo de 2026 S 10 133 0 1 $-6 230 379
Prem S Shah EVP and Group President 31 de marzo de 2026 A 64 356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer 31 de marzo de 2026 A 13 023 3 0 $4 588
Samrat S. Khichi EVP, CPO and General Counsel 31 de marzo de 2026 A 33 421 0 0 $0
Steven H Nelson EVP and President, Aetna 31 de marzo de 2026 A 2 900 1 0 $1 289
Sreekanth K Chaguturu EVP and Chief Medical Officer 1 de abril de 2024 A 23 666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer 1 de abril de 2024 A 9 426 0 0 $0
Brian A Kane EVP/President, Aetna 1 de abril de 2024 A 12 569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits 1 de abril de 2023 A 35 068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail 1 de abril de 2023 A 124 383 0 0 $0
Thomas M Moriarty EVP & General Counsel 31 de diciembre de 2022 F 315 273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices 4 de agosto de 2022 M 109 183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer 3 de abril de 2022 F 232 676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail 1 de abril de 2021 A 29 502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer 1 de abril de 2021 F 66 417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL 28 de febrero de 2021 F 25 657 0 0 $0
Jonathan E. Mayhew EVP - Transformation 2 de diciembre de 2020 F 6 855 0 0 $0
Derica W Rice EVP & President, CVS Caremark 28 de febrero de 2020 F 26 827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy 1 de abril de 2019 A 15 237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy 16 de febrero de 2018 M 45 107 0 0 $0
Robert O. Kraft EVP and President - Omnicare 3 de abril de 2017 A 92 360 0 0 $0
Andrew Sussman EVP, Clinical Services 3 de abril de 2017 A 16 433 0 0 $0
Stephen J Gold EVP & CIO 3 de abril de 2017 A 46 818 0 0 $0
Per Gh Lofberg EVP 2 de enero de 2015 M 23 419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy 30 de septiembre de 2013 M 45 955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer 1 de abril de 2013 A 17 845 0 0 $0
Douglas A Sgarro EVP and CLO 11 de mayo de 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO 16 de marzo de 2012 M 10 967 0 0 $0
Thomas M Ryan Non-Executive Chairman 3 de abril de 2011 F 1 156 702 0 0 $0
Sara Finley SVP, Gen Counsel 18 de febrero de 2011 F 29 053 0 0 $0
Michael V Ferdinandi Senior Vice President 19 de agosto de 2009 S 16 021 0 0 $0
Paula A Price Controller 12 de febrero de 2008 A 16 498 0 0 $0
Edwin M Crawford Chairman 29 de octubre de 2007 A 135 572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services 18 de junio de 2007 M 182 0 0 $0
Gregory S Weishar Vice President 3 de abril de 2006 A 30 161 0 0 $0
Larry D Solberg Senior Vice President 16 de febrero de 2006 A 5 978 0 0 $0
ROBBINS LARRY Consejero 21 de mayo de 2026 S 4 824 799 0 8 $-352 750 556
Fernando Aguirre Consejero 21 de mayo de 2026 D 10 513 0 0 $0
Jeffrey R. Balser Consejero 14 de mayo de 2026 A 15 717 0 0 $0
Douglas H. Shulman Consejero 14 de mayo de 2026 A 5 929 0 0 $0
Leslie V Norwalk Consejero 14 de mayo de 2026 A 7 376 0 0 $0
Michael F Mahoney Consejero 14 de mayo de 2026 A 6 345 0 0 $0
Anne A. Finucane Consejero 14 de mayo de 2026 A 591 0 0 $0
John E Gallina Consejero 14 de mayo de 2026 A 582 0 0 $0
Guy P Sansone Consejero 14 de mayo de 2026 A 15 106 0 0 $0
Scott J Kirby Consejero 14 de mayo de 2026 A 14 434 0 0 $0
DECOUDREAUX ALECIA A Consejero 14 de mayo de 2026 A 2 970 0 0 $0
David C Brown II Consejero 14 de mayo de 2026 A 129 316 0 0 $0
Roger N Farah Consejero 30 de noviembre de 2025 F 19 438 0 0 $0
Mary L Schapiro Consejero 21 de noviembre de 2024 A 7 585 0 0 $0
Jean Pierre Millon Consejero 21 de noviembre de 2024 A 4 514 0 0 $0
Nancy Ann Deparle Consejero 21 de noviembre de 2024 A 34 169 0 0 $0
Edward J Ludwig Consejero 2 de mayo de 2024 P 21 630 0 0 $0
William C Weldon Consejero 17 de noviembre de 2022 A 1 591 0 0 $0
Tony L White Consejero 11 de mayo de 2022 A 37 852 0 0 $0
David W Dorman Consejero 11 de mayo de 2022 A 109 875 0 0 $0
Larry J Merlo Consejero 31 de mayo de 2021 F 632 313 0 0 $0
Mark T Bertolini Consejero 20 de noviembre de 2019 A 13 773 0 0 $0
Richard M Bracken Consejero 20 de noviembre de 2019 A 15 348 0 0 $0
Richard J Swift Consejero 20 de noviembre de 2019 A 7 336 0 0 $0
Kristen Gibney Williams Consejero 9 de mayo de 2013 A 1 695 0 0 $0
C A Piccolo Consejero 14 de diciembre de 2012 S 181 461 0 0 $0
Marian L Heard Consejero 8 de noviembre de 2012 A 11 346 0 0 $0
Edwin M Banks Consejero 15 de marzo de 2012 M 23 187 0 0 $0
Terrence Murray Consejero 2 de noviembre de 2011 A 84 140 0 0 $0
Sheli Z Rosenberg Consejero 4 de noviembre de 2010 A 125 112 0 0 $0
JOYCE WILLIAM H Consejero 4 de noviembre de 2010 A 18 390 0 0 $0
Roger L Headrick Consejero 23 de mayo de 2007 P 2 200 0 0 $0
Alfred J Verrecchia Consejero 7 de marzo de 2007 A 0 0 0 $0
Don W Cornwell Consejero 22 de diciembre de 2006 A · 0 0 $0
Thomas P Gerrity Consejero 9 de noviembre de 2006 A 68 460 0 0 $0
Stanley P Goldstein Consejero 11 de mayo de 2006 J 590 967 0 0 $0
Terry R Lautenbach Consejero 21 de mayo de 2004 A 27 915 0 0 $0
Chris W Bodine · 18 de febrero de 2009 A 23 132 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Propiedad de ETFs Mantenido por 155 ETFs

20

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
IHF · iShares Trust 13,37% 1 839 467 SH 11 de septiembre de 2026 Diario
DUSA · Davis Fundamental ETF Trust 5,28% 642 932 NS 31 de julio de 2026 N-PORT
GEND · Spinnaker ETF Series 4,47% 2 080 NS 31 de julio de 2026 N-PORT
IYK · iShares Trust 4,25% 617 818 SH 11 de septiembre de 2026 Diario
CVGD · Elevation Series Trust 4,14% 54 893 NS 31 de julio de 2026 N-PORT
FMTM · EA Series Trust 3,17% 76 503 NS 31 de julio de 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2,83% 2 458 NS 31 de julio de 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2,70% 158 312 NS 31 de julio de 2026 N-PORT
SPDV · ETF Series Solutions 2,29% 28 879 NS 31 de julio de 2026 N-PORT
VHT · VANGUARD WORLD FUND 1,94% 3 824 297 SH 19 de agosto de 2026 Diario
FHLC · FIDELITY COVINGTON TRUST 1,92% 605 189 NS 31 de julio de 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 1,90% 2 167 581 SH 2 de octubre de 2026 Diario
RPV · Invesco Exchange-Traded Fund Trust 1,76% 344 218 SH 2 de octubre de 2026 Diario
REVS · Columbia ETF Trust I 1,68% 53 828 NS 31 de julio de 2026 N-PORT
IXJ · iShares Trust 1,54% 670 400 SH 11 de septiembre de 2026 Diario
CURE · Direxion Shares ETF Trust 1,53% 25 107 NS 31 de julio de 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,47% 150 785 SH 2 de octubre de 2026 Diario
PWV · Invesco Exchange-Traded Fund Trust 1,40% 298 497 SH 2 de octubre de 2026 Diario
DVY · iShares Trust 1,37% 3 384 928 SH 11 de septiembre de 2026 Diario
SPVM · Invesco Exchange-Traded Fund Trust 1,37% 21 140 SH 2 de octubre de 2026 Diario
VLUE · iShares Trust 1,35% 1 359 538 SH 11 de septiembre de 2026 Diario
CVAR · ETF Opportunities Trust 1,21% 4 966 NS 31 de julio de 2026 N-PORT
GURU · Global X Funds 1,19% 6 951 NS 31 de julio de 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1,13% 40 514 000 2 de octubre de 2026 Diario
RECS · Columbia ETF Trust I 1,09% 610 992 NS 31 de julio de 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1,04% 31 197 000 2 de octubre de 2026 Diario
FEUS · FlexShares Trust 0,97% 10 395 NS 31 de julio de 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0,95% 77 895 SH 19 de agosto de 2026 Diario
EQWL · Invesco Exchange-Traded Fund Trust 0,91% 295 291 SH 2 de octubre de 2026 Diario
FXG · First Trust Exchange-Traded AlphaDE… 0,82% 18 035 NS 31 de julio de 2026 N-PORT
LSEQ · Harbor ETF Trust 0,80% 1 171 NS 31 de julio de 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0,80% 90 467 SH 2 de octubre de 2026 Diario
FTLS · First Trust Exchange-Traded Fund III 0,80% 190 028 NS 31 de julio de 2026 N-PORT
VFMF · VANGUARD WELLINGTON FUND 0,75% 50 750 SH 19 de agosto de 2026 Diario
MTUM · iShares Trust 0,75% 1 909 551 SH 11 de septiembre de 2026 Diario
UPSD · ETF Series Solutions 0,74% 8 286 NS 31 de julio de 2026 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0,72% 12 142 NS 31 de julio de 2026 N-PORT
WLDR · Two Roads Shared Trust 0,71% 6 228 NS 31 de julio de 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0,70% 20 507 000 2 de octubre de 2026 Diario
BSCR · Invesco Exchange-Traded Self-Indexe… 0,67% 31 535 000 2 de octubre de 2026 Diario
CATH · Global X Funds 0,63% 78 905 NS 31 de julio de 2026 N-PORT
GSY · Invesco Actively Managed Exchange-T… 0,63% 24 935 000 2 de octubre de 2026 Diario
MGV · VANGUARD WORLD FUND 0,62% 801 966 SH 19 de agosto de 2026 Diario
SPMO · Invesco Exchange-Traded Fund Trust … 0,62% 1 685 814 SH 2 de octubre de 2026 Diario
LSVD · ADVISORS' INNER CIRCLE FUND 0,58% 36 106 NS 31 de julio de 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0,57% 900 NS 31 de julio de 2026 N-PORT
PFIG · Invesco Exchange-Traded Fund Trust … 0,55% 715 000 2 de octubre de 2026 Diario
VYM · VANGUARD WHITEHALL FUNDS 0,55% 5 122 611 SH 19 de agosto de 2026 Diario
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0,50% 40 184 NS 31 de julio de 2026 N-PORT
VTV · VANGUARD INDEX FUNDS 0,49% 12 134 319 SH 19 de agosto de 2026 Diario
DFUV · Dimensional ETF Trust 0,48% 710 848 NS 31 de julio de 2026 N-PORT
DFLV · Dimensional ETF Trust 0,47% 302 533 NS 31 de julio de 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0,46% 529 245 SH 2 de octubre de 2026 Diario
BSCT · Invesco Exchange-Traded Self-Indexe… 0,46% 13 367 000 2 de octubre de 2026 Diario
IWX · iShares Trust 0,45% 185 452 SH 11 de septiembre de 2026 Diario
VOOV · VANGUARD ADMIRAL FUNDS 0,45% 293 814 SH 19 de agosto de 2026 Diario
IVE · iShares Trust 0,41% 2 119 397 SH 11 de septiembre de 2026 Diario
DIVB · iShares Trust 0,41% 87 120 SH 11 de septiembre de 2026 Diario
CHRI · Global X Funds 0,41% 310 NS 31 de julio de 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0,40% 17 702 NS 31 de julio de 2026 N-PORT
IUSV · iShares Trust 0,39% 1 116 077 SH 11 de septiembre de 2026 Diario
VONV · VANGUARD SCOTTSDALE FUNDS 0,37% 774 792 SH 19 de agosto de 2026 Diario
ESG · FlexShares Trust 0,37% 4 650 NS 31 de julio de 2026 N-PORT
ILCV · iShares Trust 0,35% 49 213 SH 11 de septiembre de 2026 Diario
IWD · iShares Trust 0,33% 2 852 019 SH 11 de septiembre de 2026 Diario
GLBL · Pacer Funds Trust 0,32% 34 NS 31 de julio de 2026 N-PORT
EGLE · Global X Funds 0,31% 65 NS 31 de julio de 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0,30% 57 429 SH 19 de agosto de 2026 Diario
OEF · iShares Trust 0,26% 540 125 SH 11 de septiembre de 2026 Diario
INFO · Harbor ETF Trust 0,25% 20 350 NS 31 de julio de 2026 N-PORT
MGC · VANGUARD WORLD FUND 0,25% 255 122 SH 19 de agosto de 2026 Diario
ESGV · VANGUARD WORLD FUND 0,23% 290 253 SH 19 de agosto de 2026 Diario
TOPC · iShares Trust 0,23% 777 SH 11 de septiembre de 2026 Diario
IWL · iShares Trust 0,22% 49 933 SH 11 de septiembre de 2026 Diario
VV · VANGUARD INDEX FUNDS 0,21% 1 490 162 SH 19 de agosto de 2026 Diario
XYLD · Global X Funds 0,21% 64 877 NS 31 de julio de 2026 N-PORT
XTR · Global X Funds 0,21% 96 NS 31 de julio de 2026 N-PORT
XVV · iShares Trust 0,21% 14 653 SH 11 de septiembre de 2026 Diario
EUSA · iShares, Inc. 0,21% 41 666 SH 11 de septiembre de 2026 Diario
XRMI · Global X Funds 0,21% 990 NS 31 de julio de 2026 N-PORT
PTLC · Pacer Funds Trust 0,21% 64 355 NS 31 de julio de 2026 N-PORT
DFSU · Dimensional ETF Trust 0,21% 44 781 NS 31 de julio de 2026 N-PORT
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0,20% 174 338 NS 31 de julio de 2026 N-PORT
BKLC · BNY Mellon ETF Trust 0,20% 106 735 NS 31 de julio de 2026 N-PORT
XYLG · Global X Funds 0,20% 1 250 NS 31 de julio de 2026 N-PORT
VOTE · TCW ETF Trust 0,20% 21 382 NS 31 de julio de 2026 N-PORT
ADME · ETF Series Solutions 0,20% 5 697 NS 31 de julio de 2026 N-PORT
XCLR · Global X Funds 0,20% 69 NS 31 de julio de 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0,20% 33 144 255 SH 19 de agosto de 2026 Diario
TOV · EA Series Trust 0,20% 5 061 NS 31 de julio de 2026 N-PORT
ACIO · ETF Series Solutions 0,20% 44 949 NS 31 de julio de 2026 N-PORT
LRGF · iShares Trust 0,20% 76 567 SH 11 de septiembre de 2026 Diario
DFUS · Dimensional ETF Trust 0,19% 389 482 NS 31 de julio de 2026 N-PORT
VOXP · Advisors Series Trust 0,19% 108 NS 31 de julio de 2026 N-PORT
QVML · Invesco Exchange-Traded Fund Trust … 0,19% 37 946 SH 2 de octubre de 2026 Diario
SPUU · Direxion Shares ETF Trust 0,19% 4 814 NS 31 de julio de 2026 N-PORT
VONE · VANGUARD SCOTTSDALE FUNDS 0,19% 212 337 SH 19 de agosto de 2026 Diario
QDPL · Pacer Funds Trust 0,19% 30 732 NS 31 de julio de 2026 N-PORT
EVUS · iShares Trust 0,19% 7 499 SH 11 de septiembre de 2026 Diario
IVV · iShares Trust 0,19% 16 082 099 SH 11 de septiembre de 2026 Diario
RSP · Invesco Exchange-Traded Fund Trust 0,18% 2 046 250 SH 2 de octubre de 2026 Diario
SIZE · iShares Trust 0,18% 8 166 SH 11 de septiembre de 2026 Diario
FEX · First Trust Exchange-Traded AlphaDE… 0,18% 27 242 NS 31 de julio de 2026 N-PORT
ILCB · iShares Trust 0,18% 24 548 SH 11 de septiembre de 2026 Diario
VTI · VANGUARD INDEX FUNDS 0,18% 40 509 855 SH 19 de agosto de 2026 Diario
VTHR · VANGUARD SCOTTSDALE FUNDS 0,18% 108 067 SH 19 de agosto de 2026 Diario
IWB · iShares Trust 0,17% 888 287 SH 11 de septiembre de 2026 Diario
IYY · iShares Trust 0,17% 54 746 SH 11 de septiembre de 2026 Diario
USCL · iShares Trust 0,17% 50 655 SH 11 de septiembre de 2026 Diario
FTA · First Trust Exchange-Traded AlphaDE… 0,17% 22 631 NS 31 de julio de 2026 N-PORT
IWV · iShares Trust 0,17% 354 060 SH 11 de septiembre de 2026 Diario
PBP · Invesco Exchange-Traded Fund Trust 0,17% 7 610 SH 2 de octubre de 2026 Diario
TILT · FlexShares Trust 0,17% 34 918 NS 31 de julio de 2026 N-PORT
DCOR · Dimensional ETF Trust 0,17% 53 112 NS 31 de julio de 2026 N-PORT
DFAU · Dimensional ETF Trust 0,17% 197 043 NS 31 de julio de 2026 N-PORT
ITOT · iShares Trust 0,17% 1 661 154 SH 11 de septiembre de 2026 Diario
HCMT · Direxion Shares ETF Trust 0,16% 8 880 NS 31 de julio de 2026 N-PORT
PBUS · Invesco Exchange-Traded Fund Trust … 0,16% 220 879 SH 2 de octubre de 2026 Diario
EQAL · Invesco Exchange-Traded Fund Trust … 0,16% 15 103 SH 2 de octubre de 2026 Diario
ACVF · ETF Opportunities Trust 0,16% 2 271 NS 31 de julio de 2026 N-PORT
DYNF · BlackRock ETF Trust 0,16% 675 214 SH 11 de septiembre de 2026 Diario
SPXL · Direxion Shares ETF Trust 0,15% 99 749 NS 31 de julio de 2026 N-PORT
TOK · iShares Trust 0,14% 3 579 SH 11 de septiembre de 2026 Diario
PHDG · Invesco Actively Managed Exchange-T… 0,14% 1 007 SH 2 de octubre de 2026 Diario
URTH · iShares, Inc. 0,13% 114 536 SH 11 de septiembre de 2026 Diario
OMFL · Invesco Exchange-Traded Self-Indexe… 0,13% 70 115 SH 2 de octubre de 2026 Diario
DFAC · Dimensional ETF Trust 0,12% 539 188 NS 31 de julio de 2026 N-PORT
ACWI · iShares Trust 0,12% 406 018 SH 11 de septiembre de 2026 Diario
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,11% 1 069 623 SH 19 de agosto de 2026 Diario
DXUV · Dimensional ETF Trust 0,10% 5 157 NS 31 de julio de 2026 N-PORT
QLC · FlexShares Trust 0,09% 8 960 NS 31 de julio de 2026 N-PORT
FAB · First Trust Exchange-Traded AlphaDE… 0,08% 1 368 NS 31 de julio de 2026 N-PORT
CRBN · iShares Trust 0,05% 6 619 SH 11 de septiembre de 2026 Diario
FBCG · FIDELITY COVINGTON TRUST 0,05% 35 048 NS 31 de julio de 2026 N-PORT
GLOF · iShares Trust 0,02% 478 SH 11 de septiembre de 2026 Diario
LGDX · Tidal Trust III 0,02% 251 NS 31 de julio de 2026 N-PORT
GTOS · Invesco Actively Managed Exchange-T… 0,02% 21 000 2 de octubre de 2026 Diario
GTO · Invesco Actively Managed Exchange-T… 0,01% 419 000 2 de octubre de 2026 Diario
PEVC · Pacer Funds Trust 0,01% 3 NS 31 de julio de 2026 N-PORT
NEAR · iShares U.S. ETF Trust 0,01% 600 000 SH 11 de septiembre de 2026 Diario
DFVX · Dimensional ETF Trust 0,01% 517 NS 31 de julio de 2026 N-PORT
BIV · VANGUARD BOND INDEX FUNDS · · 15 de julio de 2026 Diario
BLV · VANGUARD BOND INDEX FUNDS · · 15 de julio de 2026 Diario
BSV · VANGUARD BOND INDEX FUNDS · · 15 de julio de 2026 Diario
BND · VANGUARD BOND INDEX FUNDS · · 15 de julio de 2026 Diario
VCRB · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VPLS · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VSDB · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VGMS · VANGUARD MALVERN FUNDS · · 15 de julio de 2026 Diario
VCSH · VANGUARD SCOTTSDALE FUNDS · · 15 de julio de 2026 Diario
VCIT · VANGUARD SCOTTSDALE FUNDS · · 15 de julio de 2026 Diario
VCLT · VANGUARD SCOTTSDALE FUNDS · · 15 de julio de 2026 Diario
VTC · VANGUARD SCOTTSDALE FUNDS · · 30 de julio de 2026 Diario
BNDW · VANGUARD SCOTTSDALE FUNDS · · 30 de julio de 2026 Diario
VCEB · VANGUARD WORLD FUND · · 30 de julio de 2026 Diario

CVS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

21
calificación · 33 analistas COMPRA
Objetivo mediano $116.00 +34,2%
8 24,2% Compra fuerte
20 60,6% Compra
5 15,2% Mantener
0 0,0% Venta
0 0,0% Venta fuerte

Precio objetivo a 12 meses

25 analistas · 2026-09-28

Objetivo medio $116.28 +34,5%

← Por Debajo de Todos los Objetivos Precio Actual $86.46
Mín$103.00 Media$116.28 Máx$148.00

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

22

Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
CVS $100.87B 57.1 7.8% 0.44% 2.4% ·
CI $72.51B 12.4 11.2% 2.2% 14.4% ·
DGX $19.09B 19.8 11.8% 9.0% 14.2% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
GH $13.34B -30.8 32.9% -42.4% 205.7% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8% ·
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
HIMS · 63.7 59.0% 5.5% 23.3% 73.8%
CHE · 23.3 4.1% 10.5% 24.4% ·

Últimas noticias Noticias recientes que mencionan a esta empresa

23

Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa

25

Ninguna señal abierta en este momento — ninguna tarjeta está completada, y eso es honesto.

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

26

Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Fuente: SEC 10-Q presentada el Ago 5, 2026